• Client List
 • Request Client Information
 • Client Press Releases
 • Client Events

11/20/2008	RHEI PHARMACEUTICALS ELECTS MRS. ZHENG HONG TO BOARD OF DIRECTORS
11/18/2008	TorreyPines Therapeutics Licenses Posiphen™, Bisnorcymcerine and Phenserine to QR Pharma
11/13/2008	Micromet to Present Interim Data from Two Studies for T Cell Engaging BiTE Antibody Blinatumomab at American Society of Hematolgy Annual Meeting
11/12/2008	TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
11/12/2008	TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
11/10/2008	METHYLGENE REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS
11/10/2008	TorreyPines Therapeutics Sells Alzheimer’s Disease Genetics Program to Eisai
11/10/2008	MediciNova Reports Third Quarter 2008 Results
11/10/2008	Researchers to Present Additional Data on Soliris® (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
11/6/2008	Living Cell Technologies Reports on 12-Month Clinical Effects of DiabeCell® at Annual General Meeting
11/4/2008	Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
10/29/2008	Theratechnologies and EMD Serono Announce Collaboration and Licensing Agreement for Tesamorelin in the United States
10/27/2008	METHYLGENE PRESENTS PRECLINICAL DATA FOR MGCD290, A HOS2 FUNGAL INHIBITOR, AT JOINT ICAAC/IDSA ANNUAL MEETING
10/27/2008	METHYLGENE REACQUIRES RIGHTS TO MGCD0103 FROM CELGENE AND IMPLEMENTS STRATEGIC PLAN TO FOCUS ON DEVELOPMENT OF PROPRIETARY CLINICAL PIPELINE
10/23/2008	ALEXION REPORTS THIRD QUARTER 2008 RESULTS
10/23/2008	Living Cell Technologies Expands Breeding Capability with New Production Facility
10/22/2008	METHYLGENE PRESENTS PRECLINICAL BIOMARKER DATA FOR MGCD265 AT THE 20th EORTC-NCI-AACR-SYMPOSIUM
10/21/2008	Living Cell Technologies Receives Health Minister’s Approval to Start Leading Edge Live Cell Therapy Clinical Trial in New Zealand for Diabetics
10/21/2008	Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
10/20/2008	TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
10/17/2008	Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions
10/15/2008	METHYLGENE INITIATES PHASE I CLINICAL STUDY WITH MGCD290 FOR FUNGAL INFECTIONS
10/13/2008	CalciMedica Exercises Option to Acquire Additional Intellectual Property from TorreyPines Therapeutics
10/8/2008	CENOMED AND TORREYPINES THERAPEUTICS ENTER INTO LICENSING AGREEMENT
10/3/2008	Micromet Closes $40 Million Private Equity Placement
10/2/2008	METHYLGENE RECEIVES CLINICAL TRIAL APPROVAL FROM HEALTH CANADA FOR ITS PROPRIETARY PRODUCT CANDIDATE MGCD290
10/1/2008	TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting with FDA for Tezampanel
9/30/2008	Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
9/25/2008	ALEXION’S SOLIRIS® RECEIVES 2008 PRIX GALIEN USA AWARD FOR BEST BIOTECHNOLOGY PRODUCT
9/25/2008	TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
9/19/2008	METHYLGENE EXERCISES RIGHT TO CONVERT MGCD0103 COLLABORATION WITH CELGENE TO PRE-DETERMINED ROYALTY AND MILESTONE ARRANGEMENT
9/18/2008	Data from MediciNova’s Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis Presented at the World Congress for Treatment and Research in MS (WCTRIMS)
9/15/2008	Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
9/15/2008	Micromet Presents Data at ESMO 2008 on Anti- EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
9/9/2008	MediciNova Reports Positive Preliminary Results from Phase II Clinical Trial of MN-221 in Moderate to Severe Asthma Patients
9/2/2008	Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
8/26/2008	TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
8/25/2008	RHEI PHARMACEUTICALS APPOINTS DR. GEERT CAUWENBERGH AS CHIEF EXECUTIVE OFFICER
8/15/2008	METHYLGENE AND CELGENE PROVIDE UPDATE ON SUSPENSION OF NEW ENROLLMENT IN MGCD0103 CLINICAL TRIALS
8/11/2008	MediciNova Reports Second Quarter 2008 Results
8/8/2008	REDPOINT BIO REPORTS SECOND QUARTER AND SIX MONTH 2008 RESULTS
8/7/2008	Micromet, Inc. Reports Second Quarter 2008 Financial Results
8/7/2008	ALEXION SECURES U.S. PATENT FOR ALXN6000, A FIRST-IN-CLASS ANTI-CD200 MONOCLONAL ANTIBODY
8/4/2008	NEXMED CONFIRMS PUBLICATION OF NEW FEMPROX DATA IN THE JOURNAL OF SEXUAL MEDICINE
7/30/2008	METHYLGENE REPORTS SECOND QUARTER 2008 FINANCIAL RESULTS
7/29/2008	ALEXION REPORTS SECOND QUARTER 2008 RESULTS
7/22/2008	NEXMED RECEIVES FDA RESPONSE FOR ED PRODUCT
7/22/2008	METHYLGENE AND CELGENE ANNOUNCE PRECAUTIONARY SUSPENSION OF NEW ENROLLMENTS INTO MGCD0103 CLINICAL TRIALS
7/21/2008	REXAHN PHARMACEUTICALS RECEIVES U.S. PATENT FOR NEW CANCER COMPOUNDS
7/1/2008	NEXMED RECEIVES CASH INFUSION OF $5.75 MILLION
6/30/2008	Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
6/25/2008	METHYLGENE ANNOUNCES THE INITIATION OF A RANDOMIZED, THREE-ARM PHASE II TRIAL OF MGCD0103 IN COMBINATION WITH VIDAZA IN PATIENTS WITH HIGH-RISK MDS OR AML
6/24/2008	Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
6/23/2008	MediciNova Initiates Phase II Clinical Trial of MN-221 in Moderate to Severe Asthma Patients
6/12/2008	METHYLGENE INITIATES SECOND PHASE I CLINICAL TRIAL WITH MGCD265, A MULTI-TARGETED (C-MET) KINASE INHIBITOR IN PATIENTS WITH SOLID TUMORS
6/12/2008	Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
6/5/2008	Micromet’s BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin’s Lymphoma
6/4/2008	TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
6/3/2008	METHYLGENE REPORTS CLINICAL DATA FROM A PHASE II STUDY EVALUATING MGCD0103 IN RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS AT THE 44TH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
6/3/2008	NEXMED CONFIRMS PUBLICATION ON ANTI-FUNGAL PRODUCT
6/2/2008	METHYLGENE REPORTS CLINICAL DATA FOR MGCD0103 AT THE 44TH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
5/16/2008	CLINICAL DATA FOR METHYLGENE’S MGCD0103 TO BE PRESENTED AT THE 2008 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
5/14/2008	NEXMED RECEIVES COMMITMENT FOR $3 MILLION LINE OF CREDIT
5/13/2008	TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
5/12/2008	MediciNova Reports First Quarter 2008 Results
5/12/2008	MethylGene Reports First Quarter 2008 Financial Results
5/9/2008	REDPOINT BIO REPORTS FIRST QUARTER 2008 RESULTS
5/8/2008	NEXMED CONFIRMS DATA PRESENTATIONS ON ANTI-FUNGAL PRODUCT AT TWO PHARMA CONFERENCES
5/1/2008	TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
4/30/2008	ALEXION REPORTS FIRST QUARTER 2008 RESULTS
4/23/2008	Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
4/16/2008	METHYLGENE INITIATES PHASE I CLINICAL TRIAL FOR ITS MULTI-TARGETED(C-MET) KINASE INHIBITOR, MGCD265,IN SOLID TUMOR CANCERS
4/16/2008	METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS MULTI-TARGETED (C-MET) KINASE INHIBITOR, MGCD265, AT AACR ANNUAL MEETING
4/15/2008	METHYLGENE PROVIDES UPDATE ON ITS MGCD0103 HDAC INHIBITOR COLLABORATION WITH CELEGENE
4/14/2008	Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
4/14/2008	Micromet Demonstrates that the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted into Highly Potent, T Cell-engaging BiTE Antibodies
4/14/2008	Micromet Presents Safety and Efficacy Data from Primate Studies with Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4/14/2008	METHYLGENE PRESENTS CLINICAL BIOMARKER DATA FOR MGCD0103 AND PRECLINICAL EFFICACY DATA IN COMBINATION WITH TAXANES AT AACR ANNUAL MEETING
4/7/2008	MediciNova Reports Clinical Results from Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis
4/7/2008	Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
4/4/2008	METHYLGENE ANNOUNCES ANNUAL MEETING OF SHAREHOLDERS AND CORRECTS PREVIOUSLY DISCLOSED INTERIM DATA FOR TRIAL 005
4/2/2008	MediciNova to Present Additional Clinical Data Demonstrating Potential Neuroprotection Benefits of MN-166 in Multiple Sclerosis at the 18th Meeting of the European Neurological Society
3/31/2008	MediciNova Initiates Phase II Clinical Trial of MN-221 in Status Asthmaticus Patients
3/31/2008	Gamma Secretase Modulators Show Promise in Alzheimer’s Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
3/27/2008	METHYLGENE ANNOUNCES WORLDWIDE RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH OTSUKA PHARMACEUTICAL CO. LTD.
3/26/2008	TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
3/25/2008	Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development
3/20/2008	Alexion Completes Enrollment in AEGIS Registration Study of Soliris ®(eculizumab) in Patients with PNH in Japan
3/18/2008	TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
3/17/2008	MediciNova Reports Fourth Quarter and Full Year 2007 Results
3/13/2008	Glycotex Completes Enrollment in Phase IIa Study of Lead Product Candidate GLYC-101 for Wound Healing
3/11/2008	REDPOINT BIO CORPORATION RECEIVES U.S. PATENT FOR METHOD OF IDENTIFYING MODULATORS OF KEY ION CHANNEL INVOLVED IN TASTE SIGNALING
3/10/2008	REDPOINT BIO CORPORATION ANNOUNCES DISCOVERY OF MOLECULAR MECHANISM FOR THYMOL TASTE TRANSDUCTION
3/10/2008	REDPOINT BIO REPORTS FOURTH QUARTER AND YEAR-END 2007 RESULTS
3/7/2008	METHYLGENE REPORTS FOURTH QUARTER AND FULL YEAR 2007 FINANCIAL RESULTS
3/5/2008	NEXMED CONFIRMS ACCEPTANCE OF NDS IN CANADA
2/14/2008	TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
2/14/2008	ALEXION ACQUIRES ALL RIGHTS TO OMRF PATENTS RELATED TO SOLIRIS®
2/14/2008	Alexion Reports Fourth Quarter and Full Year 2007 Results
2/14/2008	METHYLGENE AND PHARMION ANNOUNCE U.S. ORPHAN DRUG DESIGNATION GRANTED FOR MGCD0103 FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA
2/11/2008	METHYLGENE AND PHARMION ANNOUNCE ORPHAN DRUG DESIGNATION GRANTED BY THE EUROPEAN MEDICINES AGENCY (EMEA) FOR MGCD0103 FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA
2/8/2008	MEDICINOVA REPORTS CASH, CASH EQUIVALENTS AND SHORT-TERM MARKETABLE SECURITIES AS OF DECEMBER 31, 2007 (UNAUDITED)
2/6/2008	METHYLGENE EXERCISES RIGHT TO OPT-OUT OF HDAC NEURODEGENERATIVE COLLABORATION WITH ENVIVO
2/5/2008	Multiple Dose Clinical Trial of TorreyPines Therapeutics’ Tezampanel Demonstrates Compound is Safe and Well-Tolerated
2/1/2008	MediciNova’s MN-166 Reduces Persistent Black Hole Formation
1/28/2008	METHYLGENE REPORTS MGCD0103 CLINICAL DATA AT THE 2008 GASTROINTESTINAL CANCERS SYMPOSIUM
1/14/2008	Access Licenses MuGard™ to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
1/9/2008	METHYLGENE AND PHARMION START PHASE II COMBINATION CLINICAL TRIAL WITH MGCD0103 AND VIDAZA® IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA OR NON-HODGKIN LYMPHOMA
1/7/2008	Alexion Commences Dosing in AEGIS Registration Study
12/20/2007	Redpoint Bio Names Joseph A. Mollica, Ph.D. Chairman of the Board
12/14/2007	Redpoint Bio Signs Research & Technology Development Agreement with The Coca-Cola Company
12/14/2007	Micromet Announces Changes in Management Team
12/11/2007	Alexion Pharmaceuticals, Inc PNH Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris® Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
12/10/2007	METHYLGENE AND PHARMION PRESENT FAVORABLE CLINICAL DATA FROM COMBINATION MGCD0103/VIDAZA® STUDY IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOGENOUS LEUKEMIA AT THE 49th AMERICAN SOCIETY OF HEMATOLOGY (ASH) MEETING
12/10/2007	Alexion Pharmaceuticals, Inc. LONG-TERM SOLIRIS® THERAPY IMPROVED OR STABILIZED KIDNEY FUNCTION IN PATIENTS WITH PNH
12/10/2007	Micromet and MedImmune Present New Clinical Data for MT103 at the American Society of Hematology Annual Meeting Suggesting Potent Single-Agent Activity in Patients with Relapsed Mantle Cell and Follicular Lymphoma
12/10/2007	Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics’ Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
12/9/2007	METHYLGENE AND PHARMION REPORT FAVORABLE RESULTS FOR PHASE II MGCD0103 SINGLE-AGENT STUDIES IN RELAPSED OR REFRACTORY LYMPHOMAS AT THE 49TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) MEETING
12/7/2007	Alexion Pharmaceuticals to Present Data on Soliris® (Eculizumab)
12/5/2007	Curidium Announces Strategic Partnership with Takeda Research Investment, Inc. -Investment Focus on Major Depressive Disorder-
12/4/2007	SOLIRIS® DEMONSTRATES REDUCTIONS IN HEMOLYSIS AND IMPROVEMENTS IN FATIGUE, OVERALL QUALITY OF LIFE AND ANEMIA IN A BROAD POPULATION OF PNH PATIENTS
11/29/2007	METHYLGENE TO PRESENT CLINICAL DATA FOR MGCD0103 AT THE 49TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY
11/15/2007	CATALYST PHARMACEUTICAL PARTNERS REPORST THIRD QUARTER 2007 FINANCIAL RESULTS
11/15/2007	NEXMED REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS
11/14/2007	PreMD Reports Third Quarter 2007 Results
11/14/2007	TorreyPines Therapeutics Reports Third Quarter 2007 Results
11/9/2007	MediciNova Reports Third Quarter 2007 Results
11/7/2007	METHYLGENE REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS
11/5/2007	SKIN CHOLESTEROL LINKED TO CARDIOVASCULAR DISEASE RISK IN ASYMPTOMATIC INDIVIDUALS
10/25/2007	MediciNova Announces Public Offering of Common Stock
10/25/2007	Alexion Reports Third Quarter 2007 Results
10/24/2007	METHYLGENE AND PHARMION REPORT PRELIMINARY MGCD0103 CLINICAL DATA AT THE 2007 AACR-NCI-EORTC INTERNATIONAL CONFERENCE
10/24/2007	PreMD Announces Valuable Data on PREVU* LT Life Insurance Product
10/23/2007	Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
10/23/2007	Micromet Is Presenting Four Posters on BiTE® Antibodies at the International AACR-NCI-EORTC Conference
10/22/2007	NEXMED FILES NDS IN CANADA
10/22/2007	Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
10/19/2007	MediciNova Reports Phase IIa Clinical Study Results for MN-305, a Treatment for Insomnia
10/18/2007	Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10/17/2007	Tezampanel, TorreyPines Therapeutics’ Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10/10/2007	METHYLGENE AND PHARMION INITIATE PHASE I COMBINATION CLINICAL TRIAL WITH MGCD0103 AND TAXOTERE® IN PATIENTS WITH SOLID TUMORS
10/9/2007	MediciNova Reports Positive Phase IIa Clinical Study Results for MN-221, a Novel Treatment for Status Asthmaticus
10/5/2007	Redpoint Bio Chief Executive Officer, Dr. Ray Salemme, Featured in CEOcast Interview
10/3/2007	PreMD Inc. Provides Corporate Update
10/2/2007	METHYLGENE PROVIDES CORPORATE UPDATE AT ITS INVESTOR EVENT
10/1/2007	REDPOINT BIO NAMES SCOTT SIEGEL, PH.D. AS VICE PRESIDENT OF CORPORATE DEVELOPMENT
9/27/2007	Positive Clinical Data on MediciNova’s Product Candidate MN-029 Presented at the 14th European Cancer Conference (ECCO 14)
9/25/2007	TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer’s Disease
9/24/2007	NEXMED FILES NDA FOR PROPRIETARY ERECTILE DYSFUNCTION TREATMENT
9/24/2007	METHYLGENE AND PHARMION ANNOUNCE ORPHAN DRUG DESIGNATION GRANTED BY THE EUROPEAN MEDICINES AGENCY (EMEA) FOR MGCD0103 FOR THE TREATMENT OF HODGKIN’S LYMPHOMA
9/19/2007	METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS CLINICAL CANDIDATE MGCD290, AN ANTIFUNGAL HISTONE DEACETYLASE INHIBITOR
9/19/2007	ALEXANDRIA REAL ESTATE EQUITIES, INC. ANNOUNCES FOLLOW-ON PUBLIC OFFERING OF 2,000,000 SHARES OF COMMON STOCK
9/19/2007	ALEXANDRIA REAL ESTATE EQUITIES, INC. DECLARES QUARTERLY CASH DIVIDEND
9/12/2007	REDPOINT BIO APPOINTS NEW BOARD MEMBERS
9/12/2007	Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer
9/11/2007	MediciNova Announces Rule 10b5-1 Stock Purchase Plan
9/10/2007	TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, A Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9/6/2007	PreMD Provides Update on 510(k) Application for PREVU* POC
9/5/2007	Redpoint Bio Chief Executive Officer, Dr. Ray Salemme, To Be Interviewed Live On Market News First
9/5/2007	AKELA PHARMA INC. ANNOUNCES POSITIVE RESULTS FOR THE EXTENSION PART OF ITS PHASE IIB FENTANYL TAIFUN® TRIAL
9/5/2007	Columbia Laboratories and DesignRxclusive Increase Access to CRINONE 8% Progesterone Gel for Uninsured Patients
9/4/2007	NATIONSHEALTH ACQUIRES DIABETES CARE & EDUCATION, INC.
8/27/2007	TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
8/27/2007	AKELA PHARMA INC. ENROLLS FIRST PATIENT IN ITS PHASE IIB CGRP TRIAL
8/23/2007	New Breast Cancer Clinical Data Accepted for Presentation at San Antonio Breast Cancer Symposium
8/21/2007	METHYLGENE AND PHARMION ANNOUNCE U.S. ORPHAN DRUG DESIGNATION GRANTED FOR MGCD0103 FOR THE TREATMENT OF HODGKIN’S LYMPHOMA
8/20/2007	NationsHealth Warrants to Expire on August 24, 2007
8/20/2007	PNH Patients Treated with Soliris™ Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8/20/2007	METHYLGENE AND PHARMION ANNOUNCE COLLABORATION TO DEVELOP SIRTUIN INHIBITORS AS ANTI-CANCER AGENTS
8/17/2007	MediciNova Reports Phase Ib Clinical Study Results for MN-221, a Novel Treatment for Preterm Labor
8/15/2007	Redpoint Bio Announces Interview with WallSt.net
8/14/2007	PreMD Reports Second Quarter 2007 Results
8/14/2007	REDPOINT BIO REPORTS SECOND QUARTER 2007 FINANCIAL RESULTS
8/14/2007	PASA Abstract to be presented at American Heart Association Conference
8/14/2007	AKELA PHARMA INC REPORTS RESULTS FOR SECOND QUARTER OF FISCAL 2007
8/14/2007	NEXMED REPORTS SECOND QUARTER 2007 FINANCIAL RESULTS
8/13/2007	TorreyPines Therapeutics Reports Second Quarter 2007 Results
8/10/2007	MediciNova Reports Second Quarter 2007 Results
8/9/2007	Data from MediciNova’s Phase II Trial of MN-166 Selected for Presentation at the 23rd Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) and the 12th Conference of Rehabilitation in Multiple Sclerosis (RIMS)
8/9/2007	NATIONSHEALTH ANNOUNCES 2007 SECOND QUARTER AND YEAR TO DATE FINANCIAL RESULTS
8/9/2007	MediciNova to Present Clinical Data on MN-029 at the 14th European Cancer Conference (ECCO 14)
8/8/2007	Micromet, Inc. Reports Second Quarter 2007 Financial Results
8/7/2007	METHYLGENE REPORTS SECOND QUARTER 2007 RESULTS
8/6/2007	TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8/1/2007	METHYLGENE REGAINS EXCLUSIVE RIGHTS TO BETA-LACTAMASE INHIBITOR PROGRAM FROM MERCK
7/30/2007	NATIONSHEALTH RECEIVES ACCREDITATION
7/25/2007	Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2007 Financial Results
7/25/2007	Alexion Reports Second Quarter 2007 Results
7/23/2007	AKELA PHARMA INC. COMPLETES PATIENT ENROLLMENT IN ITS FENTANYL TAIFUN® PHASE IIB TRIAL
7/20/2007	REDPOINT BIO CORPORATION ANNOUNCES EFFECTIVENESS OF REGISTRATION STATEMENT
7/19/2007	Micromet Promotes Carsten Reinhardt to Chief Medical Officer
7/16/2007	Alexandria Real Estate Equities, Inc. Celebrates 10th Anniversary on NYSE
7/16/2007	PreMD Signs Marketing and Distribution Agreement with AstraZeneca
7/12/2007	METHYLGENE INITIATES SINGLE-AGENT PHASE II CLINICAL TRIAL WITH ITS HDAC INHIBITOR, MGCD0103, IN PATIENTS WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
7/11/2007	TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment
7/9/2007	NEXMED ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN TWO PIVOTAL PHASE 3 STUDIES FOR ANTI-FUNGAL PRODUCT
7/9/2007	NEXMED ANNOUNCES ITS INCLUSION IN THE RUSSELL MICROCAP® INDEX
6/29/2007	NEW TICKER SYMBOL FOR REDPOINT BIO CORPORATION
6/26/2007	MaRS Selects Alexandria Real Estate Equities to Expand the MaRS Centre in the Discovery District of Toronto
6/26/2007	Publication Confirms that EpCAM, the Target for Two of Micromet’s Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
6/26/2007	MediciNova Announces New Strategic Initiative
6/22/2007	ALEXION’S SOLIRIS™ GRANTED MARKETING APPROVAL IN EUROPE FOR TREATMENT OF ALL PATIENTS WITH PNH
6/20/2007	NEXMED APPOINTS VIVIAN LIU AS CHIEF EXECUTIVE OFFICER
6/20/2007	SCOTT HORVITZ OF REDPOINT BIO NAMED CFO OF THE YEAR BY NEW JERSEY TECHNOLOGY COUNCIL
6/20/2007	Micromet Announces Definitive Agreement for $25.0 Million Private Placement
6/19/2007	American Stock Exchange Accepts PreMD’s Continued Listing Plan
6/18/2007	ROBCOR PROPERTIES, INC. MERGES WITH AND INTO ITS WHOLLY-OWNED SUBSIDIARY REDPOINT BIO CORPORATION
6/18/2007	ALEXANDRIA REAL ESTATE EQUITIES, INC. DECLARES QUARTERLY CASH DIVIDEND
6/11/2007	STUDIES SHOW EFFICACY AND SAFETY OF ALEXION’S SOLIRIS™ IN BROAD POPULATION OF PNH PATIENTS
6/6/2007	PreMD Submits 510(k) to the FDA for Expanded Regulatory Claim for PREVU* POC
6/4/2007	SOLIRIS(TM) EFFECTIVE IN PNH PATIENTS WITH HISTORY OF APLASTIC ANEMIA AND MYELODYSPLASTIC SYNDROMES
6/4/2007	METHYLGENE REPORTS PHASE I DATA ON MGCD0103 IN ADVANCED LEUKEMIAS AND MYELODYSPLASTIC SYNDROME (TRIAL 004) AT ASCO
6/4/2007	Final Data from a Phase 2 Trial Presented at ASCO Specifies Dose-dependent Activity of Adecatumumab (MT201)
6/2/2007	METHYLGENE AND PHARMION REPORT PRELIMINARY DATA FOR MGCD0103 AT THE 43rd AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
5/31/2007	ADVANCED BIOHEALING CLOSES SECOND TRANCHE OF SERIES C FINANCING
5/29/2007	PreMD Inc. Receives Notice of Allowance for a United States Patent on PREVU* LT
5/24/2007	Micromet and Nycomed Enter Into Exclusive Worldwide Collaboration to Develop and Commercialize anti-GM-CSF Antibodies for the Treatment of Inflammatory and Autoimmune Diseases
5/24/2007	METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS CLINICAL CANDIDATE MGCD290 – AN ANTIFUNGAL HISTONE DEACETYLASE INHIBITOR
5/21/2007	REDPOINT BIO RELOCATES CORPORATE HEADQUARTERS AND RESEARCH FACILITY
5/17/2007	METHYLGENE SELECTS HISTONE DEACETYLASE ANTIFUNGAL CLINICAL CANDIDATE
5/14/2007	TorreyPines Therapeutics Reports First Quarter 2007 Results
5/12/2007	Curidium Announces Strategic Partnership with Takeda Research Investment, Inc. -Investment Focus on Major Depressive Disorder-
5/11/2007	PreMD Reports First Quarter 2007 Results
5/10/2007	METHYLGENE REPORTS FIRST QUARTER 2007 RESULTS
5/10/2007	NEXMED REPORTS FIRST QUARTER 2007 FINANCIAL RESULTS
5/9/2007	Micromet, Inc. reports first quarter 2007 financial results
5/7/2007	TorreyPines Therapeutics Transfers Intellectual Property and Compounds for Treating Autoimmune Diseases to CalciMedica
5/3/2007	ALEXANDRIA REAL ESTATE EQUITIES, INC. REPORTS FIRST QUARTER 2007 RESULTS
5/1/2007	Alexion Pharmaceuticals Reports First Quarter 2007 Results
4/27/2007	CHMP ADOPTS POSITIVE OPINION FOR ALEXION’S SOLIRIS™ IN EUROPE
4/26/2007	Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
4/25/2007	RIB-X PHARMACEUTICALS AND THE MEDICAL RESEARCH COUNCIL ANNOUNCE KEY COLLABORATION
4/19/2007	MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE® Molecule
4/18/2007	Micromet and MedImmune Present Data from Preclinical Study of New BiTE® Molecule Targeting CEA
4/17/2007	METHYLGENE PRESENTS CLINCAL BIOMARKER DATA FOR MGCD0103 AT AACR ANNUAL MEETING
4/16/2007	Alexandria Real Estate Equities, Inc. Announces Filing of Resale Shelf Registration Statement
4/12/2007	NATIONSHEALTH ANNOUNCES $7.0 MILLION TERM LOAN FACILITY
4/9/2007	REDPOINT BIO CORPORATION COMPLETES FINAL CLOSING OF $33 MILLION PRIVATE PLACEMENT
4/2/2007	Data on PreMD’s New PREVU* Tape POC Format to be Presented at American Association for Clinical Chemistry Meeting
3/29/2007	PreMD Reports Fiscal 2006 Results and Provides Outlook for 2007
3/29/2007	TorreyPines Therapeutics Reports 2006 Results
3/27/2007	Scientific Founder of TorreyPines Therapeutics Honored by Alzheimer’s Association
3/27/2007	Redpoint Bio Signs Multi-Year Research & Development Collaboration and Licensing Agreement with Givaudan
3/27/2007	NEXMED REPORTS 2006 YEAR END FINANCIAL RESULTS
3/21/2007	PreMD Announces Private Placement
3/16/2007	Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment
3/16/2007	FDA APPROVES ALEXION’S SOLIRIS™ FOR ALL PATIENTS WITH PNH
3/16/2007	Micromet, Inc. reports fourth quarter and full year 2006 financial results
3/15/2007	NATIONSHEALTH ANNOUNCES 2006 FOURTH QUARTER AND ANNUAL FINANCIAL RESULTS
3/13/2007	PreMD Provides Update on 510(k) Application for PREVU* LT
3/12/2007	REDPOINT BIO CORPORATION AND ROBCOR PROPERTIES, INC. COMPLETE REVERSE MERGER AND RAISE APPROXIMATELY $20 MILLION IN PRIVATE PLACEMENT TRANSACTION
3/12/2007	TorreyPines Therapeutics Initiates Phase I Multiple Dose Clinical Trial of NGX267, A Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
3/8/2007	METHYLGENE REPORTS YEAR-END 2006 FINANCIAL RESULTS
3/7/2007	Alexandria Real Estate Equities, Inc. Elects John L. Atkins, III to the Company’s Board of Directors
3/7/2007	Publication Confirms that EpCAM, the Target for Two of Micromet’s Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
2/27/2007	Advanced BioHealing Raises $25.5 Million in Series C Financing
2/26/2007	TorreyPines Therapeutics Initiates Second Phase I Clinical Trial of NGX426, a Potential Novel Oral Treatment for Chronic Pain Conditions
2/22/2007	Micromet, Inc. to Participate in Pacific Growth Equities One on One Sessions 2007: Oncology Conference
2/22/2007	TorreyPines Therapeutics and Eisai Co., Ltd. Extend Alzheimer’s Disease Collaboration Agreement
2/15/2007	Advanced BioHealing Launches Dermagraft®
2/12/2007	Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and other Cancers
2/8/2007	Advanced BioHealing Enrolls First Patient in Celaderm™ Pilot Venous Leg Ulcer Clinical Trial
1/29/2007	Micromet Reports on First International Symposium on EpCAM Biology and Clinical Application
1/8/2007	PreMD Retains License Agreement for Cancer Patents
12/19/2006	Theratechnologies Reports Positive Phase 3 Results for TH9507 in HIV associated Lipodystrophy
12/15/2006	METHYLGENE TO INCREASE INVESTMENT IN HDAC AND KINASE (c-MET) SMALL MOLECULE PROGRAMS
12/11/2006	POSITIVE DATA REPORTED AT ASH ANNUAL MEETING FOR METHYLGENE’S MGCD0103, AN ORAL, ISOTYPE-SELECTIVE HDAC INHIBITOR
12/7/2006	METHYLGENE INITIATES PHASE II CLINICAL TRIAL WITH ITS PROPRIETARY HDAC INHIBITOR, MGCD0103, IN HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOGENOUS LEUKEMIA (AML)
12/7/2006	METHYLGENE SELECTS MULTI-TARGETED KINASE (C-MET) CLINICAL CANDIDATE FOR ONCOLOGY
12/6/2006	PreMD Announces Ontario Court Reserves Decision
12/5/2006	ARBIOS SYSTEMS CHIEF SCIENTIFIC OFFICER PRESENTS AT THE ACUTE LIVER FAILURE WORKSHOP, SPONSORED BY THE NIH
12/4/2006	METHYLGENE ANNOUNCES TWO POSTER PRESENTATIONS HIGHLIGHTING ITS LEAD HDAC INHIBITOR, MGCD0103, AT THE 48TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY
11/21/2006	PreMD Announces Order Issued in Maryland Court - Antisuit Motion Denied to Shamsuddin and Med-11 AG -
11/21/2006	ALEXION PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING OF STOCK
11/16/2006	METHYLGENE AND ENVIVO PHARMACEUTICALS FORM COLLABORATION WITH CHDI, INC., IN SUPPORT OF HDAC PROGRAM FOR HUNTINGTON’S DISEASE
11/15/2006	ALEXION PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
11/15/2006	ARBIOS SYSTEMS ANNOUNCES ADDITION OF SENIOR PERSONNEL
11/14/2006	FDA Grants Priority Review for Soliris™ (eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
11/14/2006	ALEXION PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
11/9/2006	Alexion Pharmaceuticals’ Soliris™ (Eculizumab) Data to be Presented at 2006 American Society of Hematology (ASH) Annual Meeting
11/9/2006	Micromet, Inc. reports third quarter 2006 financial results
11/9/2006	PreMD Reports Third Quarter Results
11/9/2006	DATA FROM METHYLGENE’S ONCOLOGY PROGRAMS TO BE REPORTED AT THE 18th EORTC-NCI-AACR CANCER SYMPOSIUM IN PRAGUE
11/9/2006	COLUMBIA LABORATORIES REPORTS THIRD QUARTER 2006 FINANCIAL RESULTS
11/7/2006	Columbia Laboratories Advances Clinical Development of Lidocaine Candidate
11/6/2006	Antisuit Injunction Materials Served
11/6/2006	PreMD Submits 510(k) Application to FDA for PREVU* LT
11/2/2006	TorreyPines Therapeutics Completes Phase I Trial for NGX426, a Novel Oral Treatment for Pain
11/1/2006	PreMD Announces Order Made by Judge in Ontario Court
11/1/2006	METHYLGENE ANNOUNCES THIRD QUARTER 2006 RESULTS
10/31/2006	METHYLGENE TO PRESENT AT THE RODMAN & RENSHAW AND CIBC HEALTHCARE CONFERENCES
10/26/2006	METHYLGENE INITIATES PHASE I/II COMBINATION CLINICAL TRIAL WITH ITS PROPRIETARY HDAC INHIBITOR, MGCD0103, AND GEMZAR® IN PATIENTS WITH PANCREATIC CANCER
10/25/2006	Micromet Presents New Anti-IL-2 Antibody with Unique Mode of Action
10/25/2006	Theratechnologies: last patient treated in pivotal TH9507 trial
10/25/2006	PreMD Commences Action in Ontario Court
10/24/2006	ALANTOS PHARMACEUTICALS AND SERVIER FORM COLLABORATION
10/16/2006	TorreyPines Therapeutics Initiates Phase IIb Clinical Trial in Acute Migraine for Lead Compound Tezampanel
10/12/2006	Micromet, Inc. Expands Management and Appoints Christopher P. Schnittker as Senior Vice President and Chief Financial Officer
10/4/2006	Syngenta’s corn rootworm biotech trait approved in the USA
10/4/2006	TorreyPines Therapeutics Initiates Phase I Clinical Trial of NGX426, a Novel Oral Therapy for Migraine and Neuropathic Pain
10/3/2006	Syngenta obtains first regulatory approvals for new fungicide Revus™
10/2/2006	A.P. PHARMA LICENSES APF530 TO RHEI PHARMACEUTICALS FOR DEVELOPMENT IN GREATER CHINA
10/2/2006	Final Data from Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer
9/29/2006	METHYLGENE REPORTS PRECLINICAL RESULTS OF ITS ANTIFUNGAL COMPOUND MG3290 IN COMBINATION WITH AZOLES
9/29/2006	ARBIOS GRANTED FDA ALLOWANCE TO EXPAND SEPET™ CLINICAL TRIAL ELIGIBILITY
9/27/2006	PreMD’s PREVU* LT Cleared For Sale in Canada
9/26/2006	License, Development and Supply Agreements to Terminate
9/25/2006	MorphoSys and U.S. Army Enter into Biodefense Cooperation
9/20/2006	Alexion Pharmaceuticals Submits Biologics License Application for Soliris™ (eculizumab)
9/20/2006	PreMD Receives FDA Clearance for New Handheld PREVU* Reader
9/20/2006	Soliris™ (eculizumab) Demonstrates Significant Improvement in PNH Study –Phase III TRIUMPH Study Published in New England Journal of Medicine–
9/18/2006	PreMD’s PREVU* LT Cleared For Sale in Europe
9/15/2006	METHYLGENE INITIATES PHASE II CLINICAL TRIAL WITH PROPRIETARY HDAC INHIBITOR, MGCD0103, IN B-CELL LYMPHOMA
8/22/2006	METHYLGENE’S HDAC INHIBITOR, MGCD0103, ENTERS PHASE II CLINICAL TRIAL IN PATIENTS WITH REFRACTORY OR RELAPSED HODGKIN’S LYMPHOMA
8/21/2006	MedImmune Files Investigational New Drug Application for MT103
8/16/2006	ALANTOS PHARMACEUTICALS INITIATES PHASE 1 CLINICAL STUDIES WITH LEAD COMPOUND FOR TYPE II DIABETES
8/9/2006	METHYLGENE ANNOUNCES SECOND QUARTER 2006 RESULTS
8/9/2006	Micromet, Inc. reports second quarter 2006 financial results
8/9/2006	NEXMED DEVELOPS ROOM TEMPERATURE FORMULATION OF ALPROX-TD FOR ERECTILE DYSFUNCTION
8/9/2006	NEXMED REPORTS SECOND QUARTER 2006 FINANCIAL RESULTS
8/9/2006	PreMD Reports Second Quarter Results
8/8/2006	PreMD’s New Handheld PREVU* Reader Cleared by Health Canada
8/8/2006	Alexion Pharmaceuticals Reports Second Quarter 2006 Results
8/3/2006	METHYLGENE TO PRESENT AT THE 2006 MEDICINAL CHEMISTRY GORDON CONFERENCE
8/1/2006	PreMD Receives CE Mark for New Handheld PREVU* Reader
7/27/2006	PreMD’s New LungAlert™ Test Format Presented at the 2006 AACC Annual Meeting
7/26/2006	PreMD Submits Special 510(k) Application to FDA for New Handheld PREVU* Reader
7/24/2006	TorreyPines Therapeutics Completes Second Phase I Study for NGX267, a Selective M1 Agonist for the Treatment of Alzheimer’s Disease
7/21/2006	MedImmune and Micromet Report on Novel Anti-cancer BiTE®
7/13/2006	Alexion Pharmaceuticals Purchases Biopharmaceutical Manufacturing Site in Rhode Island
7/12/2006	PreMD Reports Positive Interim Results from PREPARE Study
7/10/2006	Syngenta to acquire Conrad Fafard, Inc.: expands NAFTA lawn and garden business